Welcome

Sign out Have a question? We're here to help

Copyright © 2019 InvestorPlace Media, LLC. All rights reserved. 9201 Corporate Blvd, Rockville, MD 20850.

Atara Biotherap (ATRA)

$14.18 0.98 (6.46%)

10:22 EDT ATRA Stock Quote Delayed 15 Minutes

Volume:

Previous Close $15.16

Market Cap 623.20M

PE Ratio -3.40

EPS -4.17

Volume (Avg. Vol.) 265,933

Day's Range 14.05 - 14.92

52-Week Range 11.89 - 43.95

Dividend & Yield N/A (N/A)

ATRA Stock Predictions, Articles, and Atara Biotherap News

From InvestorPlace
From the Web

7 Disruptive Biotech Stocks to Buy for 2025

By Harriet Lefton, Writer, TipRanks Jul 31, 2019

RBC Capital has peered into its crystal ball to reveal some of the market's most exciting biotech stocks. Here are seven that stand out.

5 Biotech Stocks to Sell Amid the Latest Slaughter

By Anthony Mirhaydari, InvestorPlace Market Strategist Feb 28, 2018

These five biotech stocks are being hit particularly hard right now. Here's what investors should know about each of these stocks to sell.

Benzinga's Top Upgrades, Downgrades For September 16, 2019

From Benzinga Sep 16, 2019

Upgrades Craig-Hallum changed the rating for Cars.com Inc (NYSE: CARS) from Hold to Buy. For the second quarter, Cars.com had an EPS of $0.30, compared to year-ago quarter EPS of...

10 Biggest Price Target Changes For Monday

From Benzinga Sep 16, 2019

UBS lowered HP Inc (NYSE: HPQ) price target from $26 to $20. HP shares closed at $19.08 on Friday. Barclays cut Halliburton Company (NYSE: HAL) price target from $31 to $23....

Cowen & Co. Keeps Their Buy Rating on Atara Biotherapeutics (ATRA)

From Analyst Ratings Sep 13, 2019

Cowen & Co. analyst Phil Nadeau maintained a Buy rating on Atara Biotherapeutics (ATRA – Research Report) today. The company’s shares closed last Monday at $15.42, close to its 52-week low of $11.89. According to TipRanks.com, Nadeau is a 4-star analyst with an average return of 5.3% and a 49.9% success rate. Nadeau covers the

A Cheap Biotech Stock With a Novel Treatment for Multiple Sclerosis

From Barron's Sep 13, 2019

Researchers reported that Atara’ Biotherapeutics treatment showed hints of actually improving the condition of MS patients, instead of just slowing the disease like most available treatments.

Atara T-cell therapy shows encouraging action in early-stage MS study

From Seeking Alpha Sep 13, 2019

Preliminary data from a Phase 1 clinical trial evaluating Atara Biotherapeutics' (NASDAQ:ATRA) off-the-shelf allogeneic T-cell immunotherapy ATA188 in patients with progressive forms of multiple scler

The Daily Biotech Pulse: All Eyes On Aimmune, Ritter Stumbles In Late-Stage Study, Catalyst Shelves Offering Plans

From Benzinga Sep 13, 2019

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 11) Ardelyx Inc (NASDAQ:...

Navellier Ratings

Powered by Portfolio Grader

Total Grade

F

Strong Sell

Free Report

10 Stocks Set for Monster Growth

He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!

Download your FREE COPY!